B
Bicheng Fu
Researcher at Harbin Medical University
Publications - 3
Citations - 19
Bicheng Fu is an academic researcher from Harbin Medical University. The author has contributed to research in topics: Gene silencing & microRNA. The author has an hindex of 1, co-authored 3 publications receiving 5 citations.
Papers
More filters
Journal ArticleDOI
PIGF and Flt-1 on the surface of macrophages induces the production of TGF-β1 by polarized tumor-associated macrophages to promote lung cancer angiogenesis.
Xianglong Kong,Jianlong Bu,Junhui Chen,Boxiong Ni,Bicheng Fu,Fucheng Zhou,Sainan Pang,Jian Zhang,Shidong Xu,Changjun He +9 more
TL;DR: In this paper, two different transwell culture systems were interfered with by recombinant factor placental growth factor (re-PIGF) and the re-pIGF+anti-transforming growth factor-β1 (TGF-β 1)-neutralizing antibody (anti-TGFβ 1).
Journal ArticleDOI
Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5.
Changjun He,Xue Bai,Yingbin Li,Haobo Sun,Xianglong Kong,Bicheng Fu,Lantao Chen,Kaibin Zhu,Peng-Ju Li,Shidong Xu +9 more
TL;DR: The results of xenograft tumor in nude mice showed that silencing ACP5 could inhibit the growth of LC cells in vivo, and silenced RUNX1 inhibits LC progression through the ERK/MAPK axis by binding toACP5.
Journal ArticleDOI
microRNA-877 contributes to decreased non-small cell lung cancer cell growth via the PI3K/AKT pathway by targeting tartrate resistant acid phosphatase 5 activity
Xue Bai,Changjun He,Bicheng Fu,Xianglong Kong,Jianlong Bu,Kaibin Zhu,Wei Zheng,Fucheng Zhou,Boxiong Ni +8 more
TL;DR: It was found that miR-877 expression was lowered in LC tissues and cell lines, and correlated with clinical stage, differentiation, lymph node metastasis and prognosis of NSCLC patients and downregulated the PI3K/AKT pathway by silencing ACP5.